Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study

• Main Authors: Röhnisch, Hanna E., Kyrø, Cecilie, Olsen, Anja, Thysell, Elin, Hallmans, Göran, Moazzami, Ali A.
• Format: Article in Journal/Newspaper
• Language: unknown
• Published: figshare 2020
• Subjects: Biochemistry; Medicine; Cell Biology; Genetics; FOS Biological sciences; Neuroscience; Physiology; Biotechnology; 39999 Chemical Sciences not elsewhere classified; FOS Chemical sciences; Sociology; FOS Sociology; Cancer; Northern Sweden
• Online Access: https://dx.doi.org/10.6084/m9.figshare.c.5070875.v1; https://springernature.figshare.com/collections/Identification_of_metabolites_associated_with_prostate_cancer_risk_a_nested_case-control_study_with_long_follow-up_in_the_Northern_Sweden_Health_and_Disease_Study/5070875/1

Abstract Background Prostate cancer is the second most frequently diagnosed cancer in men. Metabolomics can potentially provide new insights into the aetiology of prostate cancer by identifying new metabolic risk factors. This study investigated the prospective association between plasma metabolite concentrations and prostate cancer risk, both overall and by stratifying for disease aggressiveness and baseline age. Methods In a case-control study nested in the Northern Sweden Health and Disease Study, pre-diagnostic concentrations of 148 plasma metabolites were determined using targeted mass spectrometry- and nuclear magnetic resonance-based metabolomics in 777 prostate cancer cases (follow-up ≥ 5 years) and 777 matched controls. Associations between prostate cancer risk and metabolite concentrations were investigated using conditional logistic regression conditioned on matching factors (body mass index, age and sample storage time). Corrections for multiple testing were performed using false discovery rate (20%) and Bonferroni. Metabolomics analyses generated new hypotheses, which were investigated by leveraging food frequency questionnaires (FFQs) and oral glucose tolerance tests performed at baseline. Results After correcting for multiple testing, two lysophosphatidylcholines (LPCs) were positively associated with risk of overall prostate cancer (all ages and in older subjects). The strongest association was for LPC C17:0 in older subjects (OR = 2.08; 95% CI 1.45–2.98; p